Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic

Nicole DeFeudis

Editor

Andrew Radin was a straight A student. So when he stopped turning in assignments in Nigam Shah’s class at Stanford University, the professor knew something …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

An­drew Radin or­ches­trates his AI dis­cov­ery plat­for­m's piv­ot to R&D with a har­mo­nious name change and eyes on the clin­ic

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Andrew Radin orchestrates his AI discovery platform's pivot to R&D with a harmonious name change and eyes on the clinic